These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 21803958)
21. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
22. Perspectives on low-density lipoprotein cholesterol goal achievement. Catapano AL Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988 [TBL] [Abstract][Full Text] [Related]
23. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Vega GL; Grundy SM Am J Cardiol; 1998 Feb; 81(4A):36B-42B. PubMed ID: 9526812 [TBL] [Abstract][Full Text] [Related]
24. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
25. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
26. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. ; Boden WE; Probstfield JL; Anderson T; Chaitman BR; Desvignes-Nickens P; Koprowicz K; McBride R; Teo K; Weintraub W N Engl J Med; 2011 Dec; 365(24):2255-67. PubMed ID: 22085343 [TBL] [Abstract][Full Text] [Related]
27. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899 [TBL] [Abstract][Full Text] [Related]
29. Do patients on statins also need niacin? Jones KW JAAPA; 2013 Jul; 26(7):9-10. PubMed ID: 23923280 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf. Al-Rasadi K; Al-Zakwani I; Al Mahmeed W; Arafah M; Al-Hinai AT; Shehab A; Al Tamimi O; Alawadhi M Curr Med Res Opin; 2014 Dec; 30(12):2429-35. PubMed ID: 25222765 [TBL] [Abstract][Full Text] [Related]
31. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia. Schonfeld G; Aguilar-Salina C; Elias N Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813 [TBL] [Abstract][Full Text] [Related]
32. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Zambon A; Zhao XQ; Brown BG; Brunzell JD Am J Cardiol; 2014 May; 113(9):1494-8. PubMed ID: 24641964 [TBL] [Abstract][Full Text] [Related]
33. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Chapman MJ; Le Goff W; Guerin M; Kontush A Eur Heart J; 2010 Jan; 31(2):149-64. PubMed ID: 19825813 [TBL] [Abstract][Full Text] [Related]
34. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Knopp RH; Paramsothy P; Atkinson B; Dowdy A Am J Cardiol; 2008 Apr; 101(8A):48B-57B. PubMed ID: 18375242 [TBL] [Abstract][Full Text] [Related]
36. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571 [TBL] [Abstract][Full Text] [Related]
37. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related]
38. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
39. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients. Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523 [TBL] [Abstract][Full Text] [Related]
40. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Levy DR; Pearson TA Clin Cardiol; 2005 Jul; 28(7):317-20. PubMed ID: 16075823 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]